Barclays PLC Caribou Biosciences, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Barclays PLC holds 129,839 shares of CRBU stock, worth $233,710. This represents 0.0% of its overall portfolio holdings.

Number of Shares

129,839

Previous 129,839 -0.0%

Holding current value

$233,710

Previous $255,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$1.56 - $2.73 $111,482 - $195,093	71,463 Added 122.42%	129,839 $255,000
Q2 2024 Aug 14, 2024	SELL	$1.62 - $5.05 $62,948 - $196,227	-38,857 Reduced 39.96%	58,376 $97,000
Q1 2024 May 15, 2024	SELL	$4.82 - $8.26 $801,267 - $1.37 Million	-166,238 Reduced 63.1%	97,233 $499,000
Q4 2023 Feb 15, 2024	BUY	$3.58 - $6.25 $33,079 - $57,750	9,240 Added 3.63%	263,471 $1.51 Million
Q3 2023 Nov 07, 2023	BUY	$4.08 - $8.14 $962,961 - $1.92 Million	236,020 Added 1296.03%	254,231 $1.22 Million
Q2 2023 Aug 03, 2023	SELL	$4.04 - $5.47 $335,243 - $453,906	-82,981 Reduced 82.0%	18,211 $77,000
Q1 2023 May 04, 2023	SELL	$4.3 - $7.78 $81,265 - $147,034	-18,899 Reduced 15.74%	101,192 $538,000
Q4 2022 Feb 13, 2023	BUY	$5.57 - $11.01 $204,363 - $403,956	36,690 Added 43.99%	120,091 $754,000
Q3 2022 Nov 03, 2022	BUY	$5.34 - $12.79 $430,895 - $1.03 Million	80,692 Added 2978.66%	83,401 $880,000
Q2 2022 Aug 12, 2022	SELL	$5.1 - $9.74 $28,865 - $55,128	-5,660 Reduced 67.63%	2,709 $15,000
Q1 2022 May 16, 2022	BUY	$8.42 - $15.32 $70,466 - $128,213	8,369 New	8,369 $77,000

Others Institutions Holding CRBU

# of Institutions

135

Shares Held

52.6M

Call Options Held

148K

Put Options Held

70.7K

View Full List

About Caribou Biosciences, Inc.

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $110M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

More about CRBU

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account